Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients

The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond to immune-checkpoint blockade. We previously reported that the treatment of colorectal cancer preclinical models with temozol...

Descripción completa

Detalles Bibliográficos
Autores principales: Crisafulli, Giovanni, Sartore-Bianchi, Andrea, Lazzari, Luca, Pietrantonio, Filippo, Amatu, Alessio, Macagno, Marco, Barault, Ludovic, Cassingena, Andrea, Bartolini, Alice, Luraghi, Paolo, Mauri, Gianluca, Battuello, Paolo, Personeni, Nicola, Zampino, Maria Giulia, Pessei, Valeria, Vitiello, Pietro Paolo, Tosi, Federica, Idotta, Laura, Morano, Federica, Valtorta, Emanuele, Bonoldi, Emanuela, Germano, Giovanni, Di Nicolantonio, Federica, Marsoni, Silvia, Siena, Salvatore, Bardelli, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394384/
https://www.ncbi.nlm.nih.gov/pubmed/35522273
http://dx.doi.org/10.1158/2159-8290.CD-21-1434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394384/
https://www.ncbi.nlm.nih.gov/pubmed/35522273
http://dx.doi.org/10.1158/2159-8290.CD-21-1434

Ejemplares similares